Grant: Operating Grant: TRANSCAN-3
McGill University
$270,250.00
Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy
EF 2021-22
Résumé
Cancer immunotherapy has revolutionized cancer care, but its efficacy is dependent on the presence and activity of T cells within the tumor. We have discovered a unique immune cell type that consumes fat (lipids) from its surroundings, called "lipid-laden macrophages" (LLM). These LLM impair the ability of T cells to access tumors, and reduce their ability to mediate immunotherapy efficacy. Therefore, people who have a lot of LLM in their tumors are less likely to respond to immunotherapy.
Our proposal will explore how LLM accumulate in tumors, and how they negatively regulate response to immunotherapy in ovarian, breast and prostate cancer. Using mouse models and patient samples, we will first study where LLM get fats from, and how these fats change their maturation and behaviour. We will then explore whether diet can be used to manipulate fat availability for LLM, and whether this in turn influences T cell function. Finally, we will explore whether targeting LLM can be combined with immunotherapy to enhance therapy efficacy.
Obesity (high body mass index) is one of the leading risk factors for all cancer related mortalities, estimated to be responsible for up to 20% of all cancer deaths. Moreover, weight is an intersectional determinant of health inequities, and leveraging diet to improve cancer therapy may reduce health disparities. These studies will help explain the relationship between diet, cancer progression and therapy response, and are clinically relevant to a substantial proportion of the adult population.
Programme
Operating Grant: TRANSCAN-3
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
460419
Name
Quail Daniela
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Cancer Society - National Office (Toronto); Canadian Cancer Society - National Office (Toronto); Fondazione Regionale per la Ricerca Biomedica (Milan, Italy); Instituto de Salud Carloss III (Spain); Spanish Association Against Cancer Scientific Foundation (Madrid, Spain); Ministero della Salute (Italy)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$270,250
Cihrequipment2
$0
Programname2
Operating Grant: TRANSCAN-3
Keyworddelim
Hormone-Dependent Neoplasms; Immunotherapy; Lipids; Single Cell Analysis; Tumor-Associated Macrophages
Abstract
Cancer immunotherapy has revolutionized cancer care, but its efficacy is dependent on the presence and activity of T cells within the tumor. We have discovered a unique immune cell type that consumes fat (lipids) from its surroundings, called "lipid-laden macrophages" (LLM). These LLM impair the ability of T cells to access tumors, and reduce their ability to mediate immunotherapy efficacy. Therefore, people who have a lot of LLM in their tumors are less likely to respond to immunotherapy.
Our proposal will explore how LLM accumulate in tumors, and how they negatively regulate response to immunotherapy in ovarian, breast and prostate cancer. Using mouse models and patient samples, we will first study where LLM get fats from, and how these fats change their maturation and behaviour. We will then explore whether diet can be used to manipulate fat availability for LLM, and whether this in turn influences T cell function. Finally, we will explore whether targeting LLM can be combined with immunotherapy to enhance therapy efficacy.
Obesity (high body mass index) is one of the leading risk factors for all cancer related mortalities, estimated to be responsible for up to 20% of all cancer deaths. Moreover, weight is an intersectional determinant of health inequities, and leveraging diet to improve cancer therapy may reduce health disparities. These studies will help explain the relationship between diet, cancer progression and therapy response, and are clinically relevant to a substantial proportion of the adult population.
Competitiondate
202112
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Quail, Daniela
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $270,250~ $0~